huUSH2A(E10-15)-c.2299delG/huUSH2A(E10-15) Mouse
제품명
huUSH2A(E10-15)-c.2299delG/huUSH2A(E10-15) Mouse
제품 ID
C002046
품종 계통
C57BL/6JCya-Ush2atm2(hUSH2A*c.2299delG)/Ush2atm1(hUSH2A Exon 10-15)/Cya
Backgroud
C57BL/6JCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huUSH2A(E10-15)-c.2299delG/huUSH2A(E10-15) Mouse (카탈로그 번호 C002046)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자명
유전자 별칭
US2, RP39, USH2, dJ1111A8.1
NCBI ID
염색체
Chr 1
MGI ID
Datasheet
품종 계통 설명
The USH2A gene encodes Usherin, a basement membrane protein containing laminin EGF-like domains, pentraxin domains, and multiple fibronectin type III repeats. Usherin plays a critical role in the development of inner ear hair cells, auditory signal transduction, and the maintenance of adhesion via interactions with fibronectin in the retinal basement membrane. Mutations in the USH2A gene disrupt the normal development and function of hair cells, impair fibronectin assembly, and compromise the adhesive properties of the retinal basement membrane, leading to hearing loss and retinitis pigmentosa (RP). The USH2A gene is the primary causative gene for Usher syndrome type II (USH2), with 75%–90% of USH2 cases linked to mutations in this gene [1]. Exon 13 of the USH2A gene harbors a hotspot for pathogenic mutations associated with USH, including two common mutations, c.2299delG and c.2276G>T, which are the subject of several therapeutic investigations. The c.2299delG mutation in exon 13 causes frameshift and premature termination codons. This mutation generates a truncated Usherin protein approximately 85% of the full-length protein, resulting in loss of Usherin function [2-5]. Currently, there are no effective therapies for Usher syndrome. Ongoing research focuses on elucidating the genetic mechanisms underlying the disorder and developing gene-based therapeutic strategies.
The huUSH2A(E10-15)-c.2299delG/huUSH2A(E10-15) mouse is a humanized disease mutation model generated by crossing the huUSH2A(E10-15)-c.2299delG mouse (Catalog No.: C001850) with the huUSH2A(E10-15) mouse (Catalog No.: C001554). This model is a heterozygous humanized Ush2a mouse carrying the pathogenic c.2299delG mutation. One allele is the wild-type human USH2A (E10-15) without mutation, while the other allele is the human USH2A carrying the c.2299delG point mutation (hUSH2A*c.2299delG). It can be used for functional studies of the USH2A gene, investigation of the pathogenic mechanism of the c.2299delG mutation, as well as efficacy evaluation and mechanism-of-action studies of USH2A-targeted therapeutic strategies such as antisense oligonucleotides (ASOs) and gene editing. This model provides an important preclinical research platform for the development of innovative therapies for Usher syndrome type II (USH2) and related inherited retinal diseases
Reference
McGee TL, Seyedahmadi BJ, Sweeney MO, Dryja TP, Berson EL. Novel mutations in the long isoform of the USH2A gene in patients with Usher syndrome type II or non-syndromic retinitis pigmentosa. J Med Genet. 2010 Jul;47(7):499-506.
Pendse ND, Lamas V, Pawlyk BS, Maeder ML, Chen ZY, Pierce EA, Liu Q. In Vivo Assessment of Potential Therapeutic Approaches for USH2A-Associated Diseases. Adv Exp Med Biol. 2019;1185:91-96. doi: 10.1007/978-3-030-27378-1_15. PMID: 31884594.
Yan D, Ouyang X, Patterson DM, Du LL, Jacobson SG, Liu XZ. Mutation analysis in the long isoform of USH2A in American patients with Usher Syndrome type II. J Hum Genet. 2009 Dec;54(12):732-8. doi: 10.1038/jhg.2009.107. Epub 2009 Oct 30. PMID: 19881469; PMCID: PMC4511341.
Dreyer B, Tranebjaerg L, Brox V, Rosenberg T, Möller C, Beneyto M, Weston MD, Kimberling WJ, Cremers CW, Liu XZ, Nilssen O. A common ancestral origin of the frequent and widespread 2299delG USH2A mutation. Am J Hum Genet. 2001 Jul;69(1):228-34. doi: 10.1086/321269. Epub 2001 Jun 8. Erratum in: Am J Hum Genet 2001 Oct;69(4):922. PMID: 11402400; PMCID: PMC1226039.
Dulla K, Slijkerman R, van Diepen HC, Albert S, Dona M, Beumer W, Turunen JJ, Chan HL, Schulkens IA, Vorthoren L, den Besten C, Buil L, Schmidt I, Miao J, Venselaar H, Zang J, Neuhauss SCF, Peters T, Broekman S, Pennings R, Kremer H, Platenburg G, Adamson P, de Vrieze E, van Wijk E. Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021 Aug 4;29(8):2441-2455. doi: 10.1016/j.ymthe.2021.04.024. Epub 2021 Apr 23.
변형 전략
The huUSH2A(E10-15)-c.2299delG/huUSH2A(E10-15) mouse is a humanized disease mutation model generated by crossing the huUSH2A(E10-15)-c.2299delG mouse (Catalog No.: C001850) with the huUSH2A(E10-15) mouse (Catalog No.: C001554).
Figure 1. Gene editing strategy of huUSH2A(E10-15) mice. The start codon of the mouse Ush2a gene is located in exon 1, whereas the start codon of the human USH2A gene resides in exon 2. Consequently, exons 10–15 of the human USH2A gene correspond to exons 9–14 of the mouse Ush2a gene. Exons 9 to 14 of the mouse Ush2a gene and their flanking sequences were replaced by exons 10 to 15 of the human USH2A gene and their respective flanking sequences.
Figure 2. Gene editing strategy of huUSH2A(E10-15)-c.2299delG mice. The c.2299delG point mutation was introduced into exon 13 of human USH2A.
응용 분야
Investigation of the pathogenic mechanisms underlying Usher syndrome (USH) and preclinical evaluation of therapeutic strategies;
Development, screening, and preclinical evaluation of USH2A-targeted therapeutics.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.